Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Moore MD, Postma E, Gray KD, Ullmann TM, Hurley JR, Goldsmith S, et al. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma. World J Surg. 2018;42(2):343-349.

Rickman DS, Schulte JH, Eilers M. The Expanding World of N-MYC-Driven Tumors. Cancer Discov. 2018;8(2):150-163.

Iyengar NM, Chen I-, Zhou XK, Giri DD, Falcone DJ, Winston LA, et al. Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. Cancer Prev Res (Phila). 2018;11(4):227-236.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, et al. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest. 2018;128(1):381-386.

Goyal A, Sharaiha RZ, Alperstein SA, Siddiqui MT. Cytologic diagnosis of adenocarcinoma on bile duct brushings in the presence of stent associated changes: A retrospective analysis. Diagn Cytopathol. 2018;46(10):826-832.

Han L, Zheng W, Zhai Y, Xie X, Zhang J, Zhang S, et al. Reference intervals of trimester-specific thyroid stimulating hormone and free thyroxine in Chinese women established by experimental and statistical methods. J Clin Lab Anal. 2018;32(4):e22344.

Alperstein S, Dilcher T, Viswanathan K, Rao RA, Siddiqui MT, Giorgadze T. Acquired myospherulosis secondary to gluteal augmentation on fine needle aspiration cytology: A diagnostic challenge. Diagn Cytopathol. 2018;46(5):438-442.

Chapman J, Geyer JT, Khanlari M, Moul A, Casas C, Connor ST, et al. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Mod Pathol. 2018;31(3):429-441.

Snodgrass R, Gardner A, Semeere A, Kopparthy VL, Duru J, Maurer T, et al. A portable device for nucleic acid quantification powered by sunlight, a flame or electricity. Nat Biomed Eng. 2018;2(9):657-665.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018;78(16):4716-4730.